How Gyros Protein Technologies Enhanced Biomarker Sensitivity with BOLD
Gyros Protein Technologies recently published results demonstrating enhanced assay performance after integrating Exazym’s BOLD (Binding Oligo Ladder Detection) signal amplification into their Gyrolab microfluidic workflows. The work confirms meaningful sensitivity improvements across three clinically relevant biomarkers—and provides the kind of independent validation that changes how researchers think about what’s possible in their own labs.
What Gyros Accomplished
The Gyros team incorporated Exazym into assay development for three biomarkers central to clinical diagnostics and research:
- Neurofilament Light Chain (NfL) — A marker of neuronal injury increasingly used in Alzheimer’s disease and other neurodegenerative conditions. Integration achieved a 10-fold improvement in signal-to-background compared to non-amplified assays.
- Tumor Necrosis Factor Alpha (TNF-α) — A key inflammatory biomarker in autoimmune and infectious disease research. The amplified assay achieved a 3-fold improvement in signal-to-background and reduced the limit of detection from less than 0.7 pg/mL to less than 0.039 pg/mL—nearly an 18-fold improvement in detection sensitivity.
- Interleukin-4 (IL-4) — A cytokine involved in immune response and inflammatory disease monitoring. Optimization of the conjugation method resulted in significant signal-to-background improvement, with limits of detection reduced from less than 0.5 pg/mL to less than 0.08–0.2 pg/mL.
For each biomarker, Gyros integrated BOLD technology with their automated Gyrolab platform and produced meaningful sensitivity improvements while preserving the system’s multiplexing capability and throughput.
Why This Matters
When independent research teams integrate a technology into their established workflows and publish the results, it demonstrates what’s possible in real-world applications. Gyros’ work shows exactly that—a team that develops biomarker assays for demanding applications shared their methodology, optimization strategies, and data, revealing the sensitivity improvements they achieved.
The Gyros data confirms that Exazym® extends assay performance without disrupting established platforms or processes. For research teams evaluating sensitivity improvements, operational compatibility is as important as the sensitivity gain itself.
The Practical Reality
Notably, the Gyros team didn’t redesign their assays or adopt new instrumentation. They incorporated BOLD directly into existing Gyrolab workflows and achieved improved sensitivity for biomarkers that require detection at very low concentrations.
The result is a practical blueprint: researchers can achieve ultra-sensitive detection on platforms they already trust, without re-engineering processes or investing in new equipment.
March 19 Webinar: Hear Directly from the Researchers
On March 19, 2026, Dr. Linda Klauss from the Gyros team will present this work in a live webinar. Registration is now open—register here to secure your spot.
Participants will have the opportunity to:
- Hear directly from the Gyros team about their methodology, optimization strategies, and results
- Learn exactly how Exazym was integrated into Gyrolab assays and why certain conditions worked better than others
- Understand the sensitivity gains achieved for each biomarker and what they mean for your research
- Get your questions answered in an interactive Q&A session with Linda and our experts
If you work with low-abundance biomarkers—whether in neurology, immunology, cardiac research, or diagnostics—this session shows you exactly how one independent lab enhanced detection without disrupting their established processes.
Learn More
A poster describing the Gyros team’s work is available for download, and registration is open for the March 19 webinar. Both offer a closer look at how independent researchers approached ultra-sensitive detection challenges and the real-world solutions they implemented.
If you’re evaluating sensitivity improvements for your research, we’re here to help. Contact us to discuss whether Exazym makes sense for your specific applications.